Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Net Margin (2016 - 2025)

Historic Net Margin for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to 332.97%.

  • Editas Medicine's Net Margin rose 1015293200.0% to 332.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 426.12%, marking a year-over-year decrease of 851800.0%. This contributed to the annual value of 733.71% for FY2024, which is 5396300.0% down from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Net Margin is 332.97%, which was up 1015293200.0% from 1438.71% recorded in Q2 2025.
  • Editas Medicine's Net Margin's 5-year high stood at 31.41% during Q4 2023, with a 5-year trough of 132683.33% in Q3 2022.
  • Over the past 5 years, Editas Medicine's median Net Margin value was 873.2% (recorded in 2021), while the average stood at 14653.19%.
  • Its Net Margin has fluctuated over the past 5 years, first crashed by -1320523700bps in 2022, then soared by 1318396500bps in 2023.
  • Over the past 5 years, Editas Medicine's Net Margin (Quarter) stood at 332.3% in 2021, then crashed by -180bps to 929.22% in 2022, then surged by 97bps to 31.41% in 2023, then tumbled by -372bps to 148.32% in 2024, then tumbled by -124bps to 332.97% in 2025.
  • Its Net Margin stands at 332.97% for Q3 2025, versus 1438.71% for Q2 2025 and 1624.37% for Q1 2025.